# Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis

> **NIH NIH U01** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2023 · $480,289

## Abstract

Project Summary
Despite advances in the treatment of hepatitis C virus (HCV), the number of liver disease-related deaths has
increased annually since 2009 due to: 1) liver disease from non-alcoholic steatohepatitis (NASH) and alcohol-
induced liver disease; and 2) mortality from hepatocellular carcinoma (HCC). The time course to progress from
compensated to decompensated cirrhosis varies based on many factors, such as race/ethnicity, etiology of
liver disease, and medical co-morbidities. Hispanics have the highest age-adjusted cirrhosis mortality rates yet
are underrepresented in the largest US cirrhosis cohort studies. To disentangle whether disparities for
underrepresented populations are due to biological, cultural, and/or socioeconomic factors requires a
prospective study in a racially and ethnically diverse population. Given that genetic variants may be associated
with cirrhosis-related complications and the frequency of these variants likely differ across populations,
analyses cannot simply focus on self-reported race/ethnicity, but rather must incorporate genetic ancestry
information due to the variable genetic admixture of the US population. Another population that has been
shown to have increased risk of hepatic decompensation, and worse survival are HIV-infected patients.
However, these data have been largely restricted to patients with HIV and viral hepatitis. In addition to
identifying the trajectory of compensated cirrhosis, there is a need to identify therapeutics to slow progression.
There are several lines of evidence to suggest that statins slow cirrhosis progression and/or decrease the risk
of decompensation. There are genetic variants/haplotypes in HMGCR associated with clinical responses to
statins that are more prevalent in certain racial/ethnic groups. How these genetic variants might impact the
response to statin therapy among patients with cirrhosis is unknown, and data from other populations may not
apply due to the diversity of the US population. This underscores the need to establish the safety and efficacy
of statins to prevent hepatic decompensation in a US population, and to assess if there are variable responses
to statin therapy that depend in part on underlying genetic variation. Our overarching goal is to develop a
longitudinal prospective cohort study of patients with compensated cirrhosis to assess trajectories of hepatic
stiffness and time to hepatic decompensation. We will enroll a subset with clinically significant portal
hypertension in a randomized controlled trial of simvastatin. By targeting a racially and ethnically diverse cohort
of patients with cirrhosis, with targeted enrollment of patients with HIV, we seek to address these aims to: 1)
determine whether changes in hepatic stiffness and time to hepatic decompensation or death differ based on
genetic ancestry and HIV status in a diverse cohort of patients with cirrhosis; 2) determine whether simvastatin
decreases the risk of hepatic decompensation or...

## Key facts

- **NIH application ID:** 10700141
- **Project number:** 5U01DK130185-03
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** David Seth Goldberg
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $480,289
- **Award type:** 5
- **Project period:** 2021-09-22 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10700141

## Citation

> US National Institutes of Health, RePORTER application 10700141, Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosis (5U01DK130185-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10700141. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*